This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
MultiCell Technologies, Inc.
Drug Names(s): LAX-202
Description: LAX-202 is a combination of an atypical antidepressant and an amino acid. LAX-202 is designed to reduce the levels of fatigue in MS patients.
Deal Structure: In January 2006, MultiCell exclusively licensed MCT-125 from Amarin. Under the terms of the agreement, Amarin could receive up to $275 million in milestone payments and cumulative royalty payments during the same period.
Partners: Amarin Corporation plc
Pink Sheet Weekly Trademark Review July 12, 2016
Additional information available to subscribers only: